Your browser doesn't support javascript.
loading
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.
Prince, Eric W; Balakrishnan, Ilango; Shah, Monil; Mulcahy Levy, Jean M; Griesinger, Andrea M; Alimova, Irina; Harris, Peter S; Birks, Diane K; Donson, Andrew M; Davidson, Nathan; Remke, Marc; Taylor, Michael D; Handler, Michael H; Foreman, Nicholas K; Venkataraman, Sujatha; Vibhakar, Rajeev.
Affiliation
  • Prince EW; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Balakrishnan I; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Shah M; University of Colorado School of Medicine, Aurora, CO, United States.
  • Mulcahy Levy JM; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Griesinger AM; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Alimova I; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Harris PS; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Birks DK; Division of Pediatric Neurosurgery, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Donson AM; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Davidson N; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Remke M; DKFZ German Cancer Research Center, University Hospital Düsseldorf, Heidelberg, Germany.
  • Taylor MD; Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada.
  • Handler MH; Division of Pediatric Neurosurgery, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Foreman NK; Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
  • Venkataraman S; University of Colorado School of Medicine, Aurora, CO, United States.
  • Vibhakar R; Division of Pediatric Neurosurgery, Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States.
Oncotarget ; 7(33): 53881-53894, 2016 Aug 16.
Article in En | MEDLINE | ID: mdl-27449089

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Cerebellar Neoplasms / Checkpoint Kinase 1 / Medulloblastoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Cerebellar Neoplasms / Checkpoint Kinase 1 / Medulloblastoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos